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Increased levels of hypoxia and hypoxia-inducible factor 1a (HIF-1a) in human sarcomas correlate with tumor progression and
radiation resistance. Prolonged antiangiogenic therapy of tumors not only delays tumor growth but may also increase hypoxia
and HIF-1a activity. In our recent clinical trial, treatment with the vascular endothelial growth factor A (VEGF-A) antibody,
bevacizumab, followed by a combination of bevacizumab and radiation led to near complete necrosis in nearly half of
sarcomas. Gene Set Enrichment Analysis of microarrays from pretreatment biopsies found that the Gene Ontology category
‘‘Response to hypoxia’’ was upregulated in poor responders and that the hierarchical clustering based on 140 hypoxia-
responsive genes reliably separated poor responders from good responders. The most commonly used chemotherapeutic drug
for sarcomas, doxorubicin (Dox), was recently found to block HIF-1a binding to DNA at low metronomic doses. In four sarcoma
cell lines, HIF-1a shRNA or Dox at low concentrations blocked HIF-1a induction of VEGF-A by 84–97% and carbonic anhydrase
9 by 83–93%. HT1080 sarcoma xenografts had increased hypoxia and/or HIF-1a activity with increasing tumor size and with
anti-VEGF receptor antibody (DC101) treatment. Combining DC101 with HIF-1a shRNA or metronomic Dox had a synergistic
effect in suppressing growth of HT1080 xenografts, at least in part via induction of tumor endothelial cell apoptosis. In
conclusion, sarcomas respond to increased hypoxia by expressing HIF-1a target genes that may promote resistance to
antiangiogenic and other therapies. HIF-1a inhibition blocks this evasive resistance and augments destruction of the tumor
vasculature.
Soft tissue sarcomas arise in nearly 10,000 persons in the
United States each year, striking individuals of all ages (me-
dian age of 50 years), with roughly 40% of patients dying of
either locoregional recurrence or distant metastasis.
1 The
treatment of primary tumors usually includes surgery and
radiation, and sometimes chemotherapy. Local recurrence af-
ter aggressive surgery alone can be as high as 33% for ex-
tremity tumors and 82% for retroperitoneal tumors.
2,3 Radia-
tion therapy has been prospectively demonstrated to decrease
local recurrence for extremity and truncal tumors,
2,4 and ret-
rospective studies suggest that radiation therapy can reduce
local recurrence for retroperitoneal and pelvic tumors.
5,6 De-
spite aggressive surgery and radiation, sarcomas adjacent to
vital structures (e.g., major vessels and nerves) and all retro-
peritoneal and pelvic tumors still have a signiﬁcant risk of
local recurrence. Furthermore, up to 50% of patients with
large, high-grade sarcomas develop distant metastases, most
frequently to the lung.
7 The beneﬁt of adjuvant chemotherapy
in preventing local and distant recurrence is modest at best.
8
It is now well established that regions within solid tumors
including sarcomas experience mild to severe hypoxia owing
to aberrant vascular function.
9 The oxygen diffusion limit
from blood vessels is about 145 lm, and thus, new tumor
vasculature or co-option of existing vessels is required for
tumors to grow beyond a microscopic size.
10 As tumors
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IJCexpand, there exists a critical balance between tumor angio-
genesis, or new blood vessel formation, and hypoxia. Tumor
cells respond to hypoxic stress through multiple mechanisms,
including stabilization of hypoxia-inducible factor 1a (HIF-
1a).
11 Stabilized HIF-a is then transported to the nucleus,
where it forms a dimer with the constitutively expressed aryl
hydrocarbon receptor nuclear translocator (ARNT) subunit.
HIF dimers then bind hypoxia-responsive element DNA
sequences and consequently activate expression of at least
150 genes whose products orchestrate adaptive responses
including those mediating tumor angiogenesis e.g., vascular
endothelial growth factor A (VEGF-A),
9 invasion (e.g.,c -
Met),
12 cellular metabolism [e.g., carbonic anhydrase 9
(CA9)],
13 and metastasis (e.g., FOXM1).
14,15 Agents targeting
HIF-1a are in various stages of clinical development,
16 and
the most commonly used chemotherapeutic drug for sarco-
mas, doxorubicin (Dox), was recently found to block HIF-1a
binding to DNA at low metronomic doses.
17
VEGF-A is likely the most important factor driving tumor
angiogenesis.
18 We have previously shown that HIF-1a upre-
gulates the expression of VEGF-A in sarcomas,
19 and circulat-
ing levels of VEGF-A are elevated on average tenfold in
patients with sarcoma compared to controls.
20 The expression
of VEGF-A in sarcomas correlates with extent of disease and
survival.
21 Inhibition of VEGF-A or its receptors can effec-
tively suppress tumor angiogenesis in mouse sarcoma mod-
els,
19,22 and numerous anti-VEGF agents are in various phases
of clinical trials or approved for patients with cancer.
23
The effect of VEGF-A inhibition on intratumoral hypoxia
and HIF-1a activity may vary between different tumors. Tu-
mor blood vessels are immature, dilated, tortuous and highly
permeable with erratic ﬂow,
24,25 and many of these abnor-
malities can be attributed to the overexpression of VEGF-
A.
26 These characteristics led to areas of hypoxia in tumors.
Administration of anti-VEGF agents can result in reduced
vessel irregularity, diameter and permeability and can transi-
ently improve the delivery of oxygen.
27 However, sustained
anti-VEGF therapy can ultimately lead to loss of tumor vessels
and increased hypoxia.
28 There has been recent signiﬁcant
controversy on the effects of VEGF inhibition on primary tu-
mor invasiveness and metastatic potential.
29 Casanovas and
coworkers
30,31 found that VEGFR-2 inhibition of RIP1-Tag2
mouse pancreatic endocrine tumors led to increased intratu-
moral hypoxia along with increased tumor invasiveness and
liver metastases, and Ebos et al.
32 found that sunitinib (which
targets VEGF and other pathways) increased liver and lung
metastases for both experimental and spontaneous metastases.
This conﬂicts with other preclinical studies showing inhibition
of metastases with VEGF inhibitors
33 as well as clinical studies
demonstrating that bevacizumab as single-agent therapies can
prolong patient survival against metastatic renal cell cancer
and other cancers.
34,35 The effects of VEGF inhibition in pri-
mary sarcomas on hypoxia, HIF-1a activity and HIF-related
phenotypes such as tumor progression, metastasis and radia-
tion response are currently unknown.
We recently completed a Phase II clinical trial of neoadju-
vant bevacizumab and radiation therapy for patients with re-
sectable soft tissue sarcomas.
36 Twenty patients with interme-
diate- or high-grade soft tissue sarcomas of  5 cm in size
received bevacizumab (an anti-VEGF-A antibody) for 2
weeks followed by 6 weeks of bevacizumab combined with
radiation therapy (50 Gy). Tumor tissue samples were
obtained before treatment and 10 days after the start of beva-
cizumab. Bevacizumab and radiation resulted in a good
response (deﬁned as  80% pathologic necrosis) in nine of 20
tumors (45%), which is over double the historical response
rate seen with radiation alone. High initial microvessel den-
sity (MVD; s ¼ 0.53, p ¼ 0.0031) and decrease in MVD after
bevacizumab alone (s ¼ 0.43, p ¼ 0.0154) signiﬁcantly corre-
lated with a good response to the combination of bevacizu-
mab and radiation. As part of this clinical trial, gene expres-
sion microarray data were obtained on tumor samples prior
to the start of treatment. Tumors with a good response versus
poor response to combination therapy with bevacizumab and
radiation were distinguished by a 24-gene signature that
included PLAUR (plasminogen activator, urokinase receptor),
a gene which is transcriptionally regulated by HIF-1a.
36
In our study, further analysis of gene expression microar-
rays from this clinical trial suggested that a strong HIF-1a
transcriptional program in sarcomas may contribute to treat-
ment resistance and progression. Thus, we analyzed anti-
VEGF treatment and HIF-1a inhibition in sarcoma cell lines
in vitro as well as in a sarcoma mouse model and demon-
strated the therapeutic potential of this novel strategy.
Material and Methods
Microarray analysis
Tumor samples were obtained from a Phase II clinical trial
of neoadjuvant bevacizumab and radiation therapy for resect-
able soft tissue sarcomas as previously described.
36 RNA was
isolated from tumor tissue using the Qiagen RNeasy kit (Qia-
gen, Valencia, CA). RNA quality was assessed using 2100
What’s new?
Despite their initial promise, anti-angiogenic therapies have been a disappointment in the clinic. One reason is that solid
tumors often become resistant to these drugs. Tumors that respond poorly to this type of therapy have increased activation
of the hypoxia-induced transcription factor HIF-1a which can enhance tumor survival and progression. In this study, the
authors report that this evasive resistance can be overcome by adding low-dose doxorubicin or shRNA to inhibit HIF-1a
activity. They are thus developing a clinical trial combining the angiogenesis inhibitor bevacizumab with metronomic
doxorubicin in sarcoma patients.
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Int. J. Cancer: 132, 29–41 (2013) V C 2012 UICCBioanalyzer (Agilent, Palo Alto, CA), and ampliﬁcation was
performed using the Illumina TotalPrep RNA Ampliﬁcation
Kit (Illumina, San Diego, CA). Ampliﬁed cRNAs were hybri-
dized on HumanRef-8 Expression BeadChips (Illumina),
which targets more than 24,000 known genes. Image analysis
was carried out using Illumina’s BeadStudio v3.0.14 Gene
Expression Module. All statistical analyses were conducted
using the statistical software R (http://www.r-project.org).
The supervised hierarchical clustering of 140 genes tran-
scriptionally regulated by HIF-1a was performed using 1   r
(Pearson’s correlation) as a distance metric with a complete
linkage. Gene Set Enrichment Analysis (GSEA) was used to
identify the Gene Ontology (GO) functional categories with
signiﬁcantly different expression between good and poor res-
ponders.
37 GO categories were obtained from MSigDB (c5
GO category; http://www.broadinstitute.org/gsea/msigdb/
index.jsp). The signiﬁcance of enrichment was measured by
phenotypic label permutation. Microarray data have been
uploaded in Gene Expression Omnibus (GEO) (GEO submis-
sion #GSE31715).
Cell lines
MS4515 mouse pleomorphic undifferentiated sarcoma cells and
MS5907 mouse pleomorphic undifferentiated sarcoma cells were
derived from genetically engineered mouse models of sarcoma
(LSL-Kras
G12D/þ/Trp53
ﬂ/ﬂ and LSL-Kras
G12D/þ; Ink4A/Arf
ﬂ/ﬂ),
w h i c hw eh a v ep r e v i o u s l yd e s c r i b e d .
22,38 HT1080 human ﬁbro-
sarcoma cells, SKLMS-1 human leiomyosarcoma cells and
DC101 hybridoma cells were obtained from the American Type
Culture Collection (ATCC). Human umbilical vein endothelial
cells (HUVECs) and human dermal microvascular endothelial
cells (HDMECs) were obtained from Lonza (Basel, Switzerland).
All endothelial cells were used within eight passages. Cancer cell
lines were actively passaged for less than 6 months from the
time that they were received from ATCC or the NCI Tumor
Repository, and the UKCCCR guidelines were followed.
39
All human and mouse sarcoma cell lines were maintained
in Dulbecco modiﬁed Eagle medium supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, 100 lg/ml strepto-
mycin and 2 mM L-glutamine. All endothelial cells were
grown in EGM-2-MV media (Lonza).
DC101 antibody was produced from DC101 hybridoma
cells using the BD CELLine 1000 system (BD Biosciences,
San Jose, CA) following the manufacturer’s instructions or
purchased from BioXCell (West Lebanon, NH). Dox was
purchased from Teva Pharmaceuticals (Petah Tivka, Israel).
In vitro assays
Cell proliferation and migration were determined as previ-
ously described.
40 In brief to determine cell proliferation,
equal numbers of cells were plated in 24-well plates and
incubated for 16 hr under normoxia (21% O2) or hypoxia
(0.5% O2) under the speciﬁed conditions. Cell number was
then determined using a thiazolyl blue tetrazolium bromide
(MTT; Sigma, St. Louis, MO) assay, with optical density read
at 550 nm with a reference wavelength of 650 nm. To deter-
mine cell migration assay, equal numbers of cells were placed
in a modiﬁed Boyden chamber under normoxia or hypoxia
under the speciﬁed conditions for 4–18 hr. Nonmotile cells
were removed from the top of the chamber insert using a
cotton swap. Cells were then washed with PBS, ﬁxed in
methanol, permeabilized with 0.1% Triton-X 100 (Sigma)
and stained with DAPI (Invitrogen, Carlsbad, CA). Cells
were imaged using an inverted Olympus IX81 ﬂuorescence
microscope using Slidemaker software (Geeknet, Fairfax,
VA). Cells were counted using ImageJ software (NIH).
shRNA
Silencing of HIF1-a was achieved via lentiviral transduction
of the following speciﬁc shRNA vectors obtained from Santa
Cruz Biotechnology (Santa Cruz, CA): human HIF-1a
shRNA sc-35561, mouse HIF-1a shRNA sc35562 and scram-
ble shRNA control sc-108080. Maximal knockdown of HIF1a
occurred 72- to 96-hr post-transduction.
Western blot analysis
For Western blot analysis of HIF-1a, cells were incubated in
21% or 0.5% oxygen for 24 hr. Samples were collected in
RIPA buffer (Sigma) containing Complete Protease Inhibitor
Cocktail (Roche Diagnostics, Indianapolis, IN), and protein
concentration was determined by BSA assay (Biorad, Hercu-
les, CA). Western blot analysis was performed for HIF-1a
using the following antibodies: HIF-1a (C-Term) Polyclonal
Antibody (1:1,000, cat. no. 10006421; Cayman Chemical, Ann
Arbor, MI) and GAPDH (1:1,000, cat. no. G9545; Sigma).
Quantitative RT-PCR
For analysis of mRNA expression, cells were incubated in
21% or 0.5% oxygen for 24 hr. RNA was isolated from cell
lines using Trizol (Invitrogen) following the manufacturer’s
instructions. Total RNA was isolated from tumor tissue pre-
served in RNA Later using RNeasy Mini Kit (Qiagen) follow-
ing the manufacturer’s instruction. RNA concentration was
determined by Nanodrop 1000 (Thermoscientiﬁc, West Palm
Beach, FL). cDNA was synthesized using the Superscript
First-Strand Synthesis System (Invitrogen) with random hex-
amers. Quantitative real-time PCR analysis was performed
using the 7900HT Fast Real-Time PCR System (Applied Bio-
systems, Foster City, CA) using 100 ng of cDNA product
and Syber Green PCR Master mix (Applied Biosystems), per
manufacturer’s instructions. Primers for human genes were
as follows: VEGF-A (for) 50-GAATGCAGACCAAAGAAA
GAC-30, (rev) 50-GTGGTGACATGGTTAATCGG-30; CA9
(for) GGTTTGGATGTATCTGCACTG-30, (rev) 50-GAATT
CACATGGACTGGCTC-30; FOXM1 (for) 50-AATCGGGTT
AAGGTTGAGGAG-30, (rev) 50-GAGAAAGGTTGTGACGA
ATAGAG-30; GAPDH (for) 50-CCCCTTCATTGAC CTCA
ACTACA-30, (rev) 50-CGCTCCTGGAGGATGGTGAT-30.
Primers for mouse genes were as follows: VEGF-A (for) 50-
GAATGCAGACCAAAGAAAGAC-30, (rev) 50-GTGGTGA
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CTGCACTG-30, (rev) 50-GAATTCACATGGACTGGCTC-30;
FOXM1 (for) 50-AATCGGGTTAAGGTTGAGGAG-30, (rev)
50-GAGAAAGGTTGTGACGAATAGAG-30; GAPDH (for)
50-CCCCTTCATTGACCT CAACTACA-30, (rev) 50-CGCT
CCTGGAGGATGGTGAT-30.
Enzyme-linked immunosorbent assays
For analysis of secreted VEGF-A protein, conditioned media
was collected after 24-hr incubation. Secreted human and
mouse VEGF-A level was measured using the following com-
mercially available enzyme-linked immunosorbent assay
(ELISA) kits: Human VEGF-A Duoset and mouse VEGF-A
Duoset (all from R&D Systems, Minneapolis, MN). Manufac-
turer’s protocols were followed, and samples were measured
in duplicate. Mean values were used as the ﬁnal concentra-
tion. ELISA plates were read using the Emax Precision
Microplate Reader (Molecular Devices, Sunnyvale, CA). Cell
population was measured by MTT assay. Optical density val-
ues from the result of ELISA were divided into the optical
density from MTT assay to normalize for cell number.
Hypoxyprobe and necrosis
Hypoxia in tumors was measured using the Hypoxyprobe
TM-
1 kit (HPI, Burlington, MA) following manufacturer’s
instructions. Standard hematoxylin and eosin (H&E) staining
was also performed on tissue sections. Images from each sec-
tion were stitched together in Adobe Photoshop to create a
large scan image of the whole section. Areas of necrosis
(based on H&E sections) and areas of hypoxia (based on
Hypoxyprobe
TM-1 staining) were quantiﬁed using ImageJ
Software.
Immunohistochemical and immunoﬂuorescence microscopy
HIF-1a immunohistochemistry of parafﬁn-embedded sections
was performed as previously described.
41 HIF-1a was stained
using mouse anti-HIF-1a Ab-4 mAb (1:10,000, NB100-105;
Novus, Littleton, CO). Sections were counterstained with he-
matoxylin. The number of HIF-1a-positive nuclei was quan-
tiﬁed by image analysis using software ImageJ (http://rsb.in-
fo.nih.gov/ij). HIF-1a-positive brown nuclei and HIF-1a-
negative blue nuclei were counted in ﬁve random photo-
graphed ﬁelds for each tumor.
CD31 immunohistochemical localization and analysis of
MVD were performed as previously described.
42 For detection
of EC apoptosis, TUNEL assay and CD31 immunoﬂuores-
cence were performed. Parafﬁn-embedded sections were
deparafﬁnized and incubated with goat anti-CD31 Ab (1:100,
SC-1506; Santa Cruz Biotechnology) overnight at 4 C. Follow-
ing washing, sections were incubated with rabbit anti-goat
Alexa 594-conjugated secondary antibody (1:500, A11080;
Molecular Probes, Carlsbad, CA) for 1 hr at room tempera-
ture. Then, sections were treated with the DeadEnd Fluoro-
metric TUNEL system (Promega, Madison, WI) to detect apo-
ptosis, following the manufacturer’s instruction. Subsequently,
sections were stained with DAPI (0.2 lg/ml) for 3 min. Images
were obtained on a Zeiss microscope and analyzed using Axio-
Vison 4.0 software (Carl Zeiss, Thornwood, NY).
Mouse studies
All mouse protocols were approved by the Massachusetts
General Hospital Subcommittee on Research Animal Care.
To generate subcutaneous ﬂank tumor, 10
6 HT1080 cells
were resuspended in 100 ll of Hank’s balanced salt solution
and injected subcutaneously into the right ﬂank of athymic
nude mice following xylazine/ketamine anesthesia. Six mice
were used for each group. Tumors were measured three times
per week for a maximum of 3 weeks, and tumor volume
(TV) was calculated by using the following formula: TV ¼
length   (width)
2   0.52. Treatment began when the TVs
were  50 mm
3, and DC101 (400 lg per mouse), isotype
control IgG1s( 4 0lg per mouse) and/or Dox (1.0 mg/kg)
were injected intraperitoneally three times a week.
Statistical analysis
Groups were compared using GraphPad 3.10 software
(InStat). p values were calculated using Student’s t-test. For
comparisons between more than two groups, treatment
groups were compared to the control group using one-way
ANOVA with Bonferroni adjustment for multiple compari-
sons. p values < 0.05 were considered signiﬁcant.
Results
From the Phase II clinical trial of neoadjuvant bevacizumab
and radiation for sarcoma described above, we had gene
expression microarray data from tumors prior to the start of
treatment.
36 We explored the differential gene expression
between tumors with a subsequent good pathological
response ( 80% necrosis) versus poor pathological response
(<80% necrosis) to bevacizumab and radiation using GSEA
of 1,454 GO categories. Overall, 14 and 18 GO categories
showed signiﬁcant (False discovery rate < 0.1) upregulation
in poor and good responders, respectively (Supporting Infor-
mation Table 1). The GO category ‘‘Response to hypoxia,’’
which contains 28 genes, was upregulated in tumors with a
poor response to bevacizumab and radiation (nominal p
value ¼ 0.08; Fig. 1a). One of the genes that most highly
contributed to the identiﬁcation of the enrichment of this
GO category set was HIF-1a. Thus, we performed a super-
vised hierarchical clustering analysis of 140 genes transcrip-
tionally regulated by HIF-1a (Supporting Information Table
2) and found that these genes reliably clustered tumors into
those with a good versus poor response to bevacizumab and
radiation (Fig. 1b). Paired biopsy specimens taken before and
after the start of bevacizumab were available for seven
patients, ﬁve of which had a good response to treatment and
two of which had a poor response. In the two tumors that
had a poor response to bevacizumab and radiation, quantita-
tive RT-PCR for VEGF-A, a HIF-1a target gene, demon-
strated signiﬁcant upregulation (Fig. 1c). These data suggest
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sarcomas may contribute to treatment resistance and tumor
progression. This analysis led to the underlying hypothesis
for our study: VEGF-A and HIF-1a play critical and interde-
pendent roles in regulating sarcoma progression.
To better determine the role of HIF-1a in various sarco-
mas, we next examined HIF-1a and HIF-1a target genes in
four sarcoma cell lines, two of human origin (HT1080
human ﬁbrosarcoma and SKLMS human leiomyosarcoma)
and two of mouse origin (MS4515 and MS5907). HIF-1a
Figure 1. (a) A Gene Set Enrichment Analysis plot of the ‘‘Response to hypoxia’’ category from Gene Ontology is shown (top). Genes (x-
axis) are ordered by their t-statistics comparing poor and good responders. The upregulated and downregulated genes in poor responders
are placed on the left and right, respectively. The enrichment score (y-axis) is a cumulative sum reﬂecting the degree of over-representation
for the genes in this category compared to the rest of the genes; a high enrichment score indicates the presence of hypoxia-related genes
among the genes that are signiﬁcantly different in the good/poor responder phenotype. The locations of the 28 hypoxia-related genes are
shown in the middle bar, with the gene symbols for the 11 genes that contribute to the maximum value of the enrichment score shown in
gray. The relative expression levels of the 11 genes are also shown in a heat map (bottom). Red and blue represent the relative
upregulation and downregulation, respectively, compared to its average expression. (b) Supervised hierarchical clustering analysis of 140
hypoxia-responsive genes. Poor and good responders are indicated by red and green, respectively. This analysis demonstrates that the vast
majority of good and poor responders can be differentiated based on the expression of hypoxia-related genes. Dendogram is shown at top.
(c) Relative mRNA levels of VEGF-A in sarcomas before and after bevacizumab (BV) treatment. Relative value is in relation to the lowest
level of expression, which was assigned a value of 1. Poor and good responders are indicated by red and green boxes, respectively. Bars
represent standard deviation. *p < 0.05 compared to pretreatment level.
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Int. J. Cancer: 132, 29–41 (2013) V C 2012 UICClevels were upregulated in all four cell lines in response to
0.5% O2 (Fig. 2a). We examined the levels of HIF-1a target
genes associated with angiogenesis (VEGF-A), metabolism
(CA9) and metastasis (FOXM1) by qRT-PCR (Fig. 2b).
VEGF-A was upregulated in all four cell lines under hypoxia
by 1.7- to 2.4-fold. In the human sarcoma cell lines, CA9 was
upregulated 18- to 36-fold, whereas FOXM1 remained rela-
tively unchanged or slightly decreased. In the mouse sarcoma
cell lines, CA9 was upregulated 24- to 49-fold, whereas
FOXM1 levels again remained relatively unchanged or
decreased slightly. We conﬁrmed changes in VEGF-A at the
protein level by measuring the secretion of VEGF-A from
these cell lines under hypoxia (Fig. 2c). VEGF-A protein
secretion increased 2.1- to 5.7-fold in all cell lines following
exposure to hypoxia. Of note, the differences in upregulation
of VEGF-A mRNA versus VEGF-A protein under hypoxic
conditions may be related to inherent differences in the cell
lines in their response to hypoxia, differences in translation
of VEGF-A mRNA or differences in secretion or degradation
of VEGF-A protein. Thus, sarcoma cell lines respond to
Figure 2. (a) Western blot analysis of HIF-1a in human and mouse sarcoma cell lines in 21% oxygen (normoxia) and 0.5% oxygen
(hypoxia). GAPDH blot serves as loading control. (b) Relative mRNA levels of VEGF-A, CA9 and FOXM1 in human and mouse sarcoma cell
lines under normoxic and hypoxic conditions. (c) VEGF-A protein secreted into media of human and sarcoma cell lines under normoxic and
hypoxic conditions. For relative value, expression level under normoxia for each cell line assigned a value of 1. Bars represent standard
deviation. *p < 0.05 compared to normoxia level.
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1a target genes.
We examined our sarcoma cell lines for the expression of
VEGF receptors 1 and 2 (VEGFR-1 and VEGFR-2) and
found little or no expression in any of these cell lines (data
not shown). Using HT1080 ﬁbrosarcoma ﬂank tumor xeno-
grafts generated in athymic nude mice, we examined the lev-
els of hypoxia and HIF-1a in control tumors and the tumors
treated with DC101, an anti-VEGFR-2 antibody. Tumor-
bearing mice were treated with DC101 or control IgG once
they reached 50 mm
3 in size. Control tumors took  12 days
to reach 1,000 mm
3 (data not shown). When analyzed for
the levels of hypoxia using Hypoxyprobe immunohistochem-
istry, hypoxia levels were found to increase in control tumors
as tumors increased from 200 to 500 mm
3, with no further
increase in hypoxia as tumor grew beyond 500 mm
3 (Fig.
3a). HT1080 xenografts treated with DC101 showed delayed
tumor growth, with tumors taking about 5–7 days longer to
reach 1,000 mm
3 in size. The levels of hypoxia in HT1080
tumors were not signiﬁcantly affected by DC101 after con-
trolling for tumor size (i.e., comparing similar-sized tumors
in each group). The levels of nuclear HIF-1a correlated with
the levels of intratumoral hypoxia, with levels increasing as
tumors increased in size from 200 to 500 mm
3 and then
remaining stable (Fig. 3b). Of note, DC101 treatment did
increase nuclear localization of HIF-1a in small tumors
(200–300 mm
3; Figs. 3c and 3d). This would suggest that
there is no direct correlation between the levels of hypoxia as
Figure 3. (a) Photos of HT1080 sarcoma xenografts treated with control IgG or DC101 and stained for hypoxia using Hypoxyprobe
TM-1.
Length of treatment (Tx) and tumor sizes at time of harvesting are listed. (b) Percent hypoxia of H1080 xenografts at various sized tumors
after treatment with control IgG or DC101. (c) Percentage of nuclei in various sized tumors treated with control IgG or DC101 staining for
HIF-1a or HIF-2a. Bars represent standard deviation. *p < 0.05 compared to control IgG group; ns, not signiﬁcant (p > 0.05). (d) Photos of
HT1080 sarcoma xenografts treated with control IgG or DC101 and stained for hypoxia HIF-1a. Tumor sizes at time of harvesting are listed.
[Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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HIF-1a protein, with the latter possibly being a more sensi-
tive measure of hypoxia. Alternatively, DC101 may have
effects on HIF-1a nuclear localization, which are independent
of hypoxia levels.
To determine the role of HIF-1a in sarcoma cell prolifera-
tion and migration in vitro and tumor growth in vivo,w e
used shRNA knockdown of HIF-1a in HT1080 sarcoma cells
that showed strong upregulation of HIF-1a in response to
0.5% hypoxia (Fig. 4a). This upregulation of HIF-1a was
effectively blocked by shRNA knockdown of HIF-1a. shRNA
knockdown in HT1080 cells inhibited proliferation under
normoxic and hypoxic conditions (Fig. 4b) and reduced the
migration of these cells under hypoxic conditions (Fig. 4c).
Following HIF-1a knockdown in MS5907 sarcoma cell lines,
we found no effect on proliferation; however, we found
decreased migration under hypoxic conditions (Supporting In-
formation Figs. S1A–S1C). HT1080 cells with stable knock-
down of HIF-1a and control HT1080 cells were then grown as
ﬂank xenografts with or without treatment with DC101. The
knockdown of HIF-1a or DC101 treatment inhibited tumor
growth; however, the combination of HIF-1a knockdown and
Figure 4. (a) Western blot analysis of HIF-1a in HT1080 cells in 21% oxygen (normoxia) and 0.5% oxygen (hypoxia) following treatment
with HIF-1a shRNA or scrambled (Scr) control shRNA. GAPDH blot serves as loading control. Proliferation (b) and migration (c) of HT1080
cells after transduction with HIF-1a shRNA or scrambled (Scr) shRNA. (d) Growth of HT1080 cell transduced with HIF-1a shRNA or scrambled
(Scr) shRNA following subcutaneous injection in athymic nude mice. Some groups treated with DC101 and IgG were used as antibody
treatment control. Metronomic doxorubicin (Dox) was given to one group. (e) Relative mRNA levels of CA9 in HT1080 tumor groups. Bars
represent standard deviation. *p < 0.05 compared to control group; ns, not signiﬁcant (p > 0.05); **p < 0.05 compared to Scr shRNA þ
IgG control group, HIF-1a shRNA þ IgG group and Scr shRNA þ DC101 group.
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4d). We assessed the levels of one HIF-1a target gene, CA9,i n
treated HT1080 tumors by qRT-PCR and found that HIF-1a
knockdown did indeed repress CA9 levels (Fig. 4e).
Lee et al.
17 found after screening 3,120 drugs from the
Johns Hopkins Drug Library that Dox is a potent inhibitor of
HIF-1a by blocking HIF-1a binding to DNA. Dox is the
most commonly used chemotherapeutic agent for soft tissue
sarcomas,
17 and thus, the use of this agent to block HIF-1a
induction of target genes in sarcomas makes therapeutic
sense. Dox blocked proliferation of all four sarcoma cell lines
and two types of endothelial cells at IC50 concentrations of
0.005 to 0.1 lM, with endothelial cells generally being more
sensitive to Dox than cancer cell lines (data now shown). As
noted earlier for the four sarcoma cell lines, VEGF-A and
CA9 were upregulated in hypoxia. For HT1080 cells, CA9
showed the most hypoxic upregulation of the four genes
examined, and low-dose Dox completely potently blocked
Figure 5. (a) Relative mRNA levels of CA9 or FOXM1 in human and mouse sarcoma cell lines under normoxia, hypoxia or hypoxia with
doxorubicin (10 lM). (b) VEGF-A protein secreted into media of human and sarcoma cell lines under normoxia, hypoxia or hypoxia with
doxorubicin (10 lM). (c) Growth of HT1080 ﬁbrosarcoma xenografts in vivo. HT1080 cells were injected subcutaneously, and growth was
monitored for 17 days. (d) Relative mRNA levels of CA9 in HT1080 tumors. (e) Percent necrosis in HT1080 tumors as determined following
H&E staining. For relative values, expression level under normoxia for each cell line or control group assigned a value of 1. Bars represent
standard deviation. *p   0.05 compared to control group; **p < 0.05 compared to control group and to other treatment groups.
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able to decrease VEGF-A secretion from all four sarcoma cell
lines following hypoxia (Fig. 5b). In HT1080 cells, we com-
pared the ability of HIF-1a shRNA and Dox to block induc-
tion of VEGF under hypoxic conditions and found that HIF-
1a and Dox blocked VEGF secretion equally (Supporting In-
formation Fig. S2). Combining HIF-1a shRNA with Dox had
no additive effect (Supporting Information Fig. S2). We next
examined the effects of DC101 and/or metronomic Dox on
HT1080 xenografts. DC101 or metronomic Dox inhibited tu-
mor growth by 30–31%, and the combination of DC101 or
metronomic Dox inhibited tumor growth by 67% (Fig. 5c).
Tumors were harvested at the end of treatment and exam-
ined for the expression of CA9. As seen in our in vitro stud-
ies, HT1080 xenografts exposed to metronomic Dox had sig-
niﬁcantly lower expression of CA9 (Fig. 5d), and
Figure 6. (a) Photos of CD31 immunohistochemical staining of HT1080 tumors along with graph showing microvessel density. Scale bar ¼
100 mm. (b) Overall apoptosis in HT1080 tumor groups. (c)Photos of coimmunoﬂuorescence for CD31 and TUNEL along with the graph of
endothelial cell-speciﬁc apoptosis. Scale bar ¼ 7 mm. Arrows point to TUNEL-positive and CD31-positive cells. Bars represent standard
deviation. *p   0.05 compared to control IgG group; **p < 0.05 compared to control IgG and DC101 groups.
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(Fig. 5e).
We next explored the effects of DC101 along with HIF-1a
inhibition (either with HIF-1a shRNA or metronomic Dox)
on tumor vasculature. Given the ﬁrst metronomic Dox likely
has off-target effects beyond HIF-1a inhibition, we examined
whether adding metronomic Dox to DC101 and HIF-1a
knockdown increased HT1080 xenograft tumor growth delay
and found that there was no signiﬁcant additional effect (Fig.
4d). Second, we examined MVD and found that DC101
reduced MVD by 42%, HIF-1a shRNA or metronomic Dox
by 25–27% and the combination of HIF-1a shRNA or Dox
and DC101 by 71–72% (Fig. 6a). Overall apoptosis in tumors
was increased by 2.3- to 4.5-fold by treatment with DC101
and/or HIF-1a inhibition (Fig. 6b), whereas endothelial cell-
speciﬁc apoptosis was increased at least twofold only with the
combination of DC101 and HIF-1a inhibition (Fig. 6c). Of
note, the addition of Dox to HIF-1a knockdown did not add
any further effect on tumor growth inhibition and also did
not further decrease MVD or increase endothelial cell-speciﬁc
apoptosis.
Given the combined VEGF and HIF-1a inhibition
appeared to have a synergistic effect on tumor vasculature,
we further examined the effect of VEGF-A deprivation plus
HIF-1a inhibition on endothelial cells in vitro. The removal
of VEGF-A from the cell culture media combined with HIF-
1a knockdown inhibited the proliferation of HUVECs under
both normoxic and hypoxic conditions (Supporting Informa-
tion Fig. S3A). Similar results were obtained when this
experiment was performed with HDMECs (data not shown).
We substituted HIF-1a genetic inhibition (i.e., HIF-1a
shRNA) with pharmacologic inhibition using low-dose Dox
in HDMECs and found a similar synergistic attenuation of
proliferation when VEGF-A withdrawal was combined with
Dox (Supporting Information Fig. S3B).
Discussion
Our study was initiated following the examination of correla-
tive science studies from a Phase II clinical trial of bevacizu-
mab and radiation therapy for sarcomas. In this clinical trial,
the addition of VEGF-A inhibition to radiation signiﬁcantly
increased the proportion of tumors with a good response to
radiation therapy to nearly 50%. Studies of tumor tissue
obtained before treatment and during treatment allowed us
to ask why the other 50% of tumors were resistant to ther-
apy. In our study, analysis of gene expression microarrays
suggested that high expression of HIF-1a and HIF-1a target
genes contributed to resistance to the combination of bevaci-
zumab and radiation. Thus, we examined the role of hypoxia
and HIF-1a in sarcoma progression as well as the combina-
tion of VEGF-A and HIF-1a inhibition in sarcomas. We
found that four different sarcoma cells lines upregulate HIF-
1a and speciﬁc HIF-1a target genes under hypoxic condi-
tions. Genetic deletion of HIF-1a using shRNA or the phar-
macologic blockade of HIF-1a binding to target DNA using
low-dose Dox act synergistically with VEGF inhibition to
suppress the growth of sarcoma xenografts. Our analysis of
treated tumors reveals that the one mechanism for this effect
is via the induction of tumor endothelial cell apoptosis. These
ﬁndings have signiﬁcant implications in the future treatment
of sarcomas with antiangiogenic therapies.
When antiangiogenic therapies were initially proposed for
inhibiting solid tumors, it was thought that such therapies
would be less susceptible to resistance given the target was
genetically stable tumor endothelial cells as opposed to genet-
ically unstable cancer cells. Now after several years of antian-
giogenic therapies being used in patients with solid tumors,
oncologists have found that antiangiogenic therapies generally
result only in a transitory inhibition or delay in tumor
growth with ultimate regrowth of tumors. Mechanisms of re-
sistance to antiangiogenic therapies include upregulation of
alternative proangiogenic signals, protection of the tumor
vasculature either by recruiting proangiogenic inﬂammatory
cells or by increasing protective pericyte coverage, accentu-
ated invasiveness of tumor cells into local tissue to co-opt
normal vasculature and increased metastatic seeding and tu-
mor cell growth in lymph nodes and distant organs.
43
Hypoxia and HIF-1a are known to play important roles in
human sarcomas. We have previously shown that the expres-
sion of HIF-1a and 25 other hypoxia-related genes in human
sarcomas is highly upregulated compared to normal tissues,
19
and hypoxia in human sarcomas is associated with a higher
risk of recurrence and decreased overall survival.
44,45 HIF-1a
upregulates the expression of VEGF-A in sarcomas,
19 and cir-
culating levels of VEGF-A are elevated on average tenfold in
patients with sarcoma compared to controls.
20 In our study, we
conﬁrmed upregulation of HIF-1a under hypoxic conditions in
four different sarcoma cell lines. The hypoxia response in terms
of target genes was fairly similar between these sarcoma cell
lines with uniform upregulation of VEGF-A and CA9.
The effect of VEGF inhibition on intratumoral hypoxia
and HIF-1a activity may vary depending on the speciﬁc tu-
mor type. The administration of anti-VEGF agents can result
in reduced vessel irregularity, diameter and permeability and
can transiently improve the delivery of oxygen.
27 However,
sustained anti-VEGF therapy can ultimately lead to loss of
tumor vessels and increased hypoxia.
28 In our study, we
found that anti-VEGFR-2 therapy with DC101 did not signif-
icantly change intratumoral hypoxia when comparing simi-
lar-sized tumors; however, DC101 did appear to increase nu-
clear localization of HIF-1a in small tumors (200–300 mm
3).
One mechanism by which VEGF inhibition and HIF-1a
inhibition synergistically inhibit sarcoma progression is via
the targeting of the tumor endothelium. Thus, VEGF inhibi-
tion likely only inhibits the vascular compartment of tumors
and has little or no effect on the cancer cell compartment.
HIF-1a, in contrast, is expressed by both endothelial cells
and sarcoma cells and may have effects on both cell types.
We analyzed these compartments separately both in vitro
and in vivo and found that synergistic effects from combined
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apoptosis were only found in the vascular compartment.
Lee et al.
17 screened more than 3,000 drugs from the
Johns Hopkins Drug Library and found that Dox at low
doses can block HIF-1a binding to DNA. In looking for a
clinically applicable inhibitor of HIF-1a for sarcomas, Dox is
a very good candidate, given that Dox is already the most
commonly used chemotherapeutic drug for sarcomas.
46 How-
ever, the traditional means of delivering Dox, that is, at maxi-
mum tolerated doses, focuses on maximizing cancer cell cyto-
toxicity rather than maximizing HIF-1a blockade. The
delivery of Dox at low, continuous doses (i.e., metronomic
doses) maximizes HIF-1a blockade,
17 and this approach has
been used in other patients with solid tumors. The adminis-
tration of metronomic Dox to heavily pretreated patients
with metastatic breast cancer resulted in a partial response in
18% of patients and stable disease in 3%.
47 We found in our
study that metronomic Dox can block HIF-1a-mediated up-
regulation of target genes, and when combined with anti-
VEGF therapy has a synergistic effect in blocking sarcoma
tumor growth.
There are several limitations to our study. One potential
criticism is that metronomic Dox is used as an inhibitor of
HIF-1a rather than more speciﬁc inhibitor of HIF-1a.D o x
is a topoisomerase II inhibitor and a commonly used che-
motherapeutic agent. Mechanistically, we conﬁrmed the
synergistic effects of HIF-1a a n dV E G Fi n h i b i t i o no nt u -
mor growth and on tumor endothelium by speciﬁcally
knocking down HIF-1a using shRNA. There are several
HIF-1a inhibitors that are in various phases of clinical de-
velopment; however, none are approved for clinical use.
48
Although Dox clearly has effects other than inhibiting
HIF-1a, the primary advantage of using metronomic Dox
in our study is that Dox is already clinically approved
for the treatment of sarcomas and that ﬁndings from our
study can be immediately translated into clinical trials
combining metronomic Dox with VEGF inhibitors such as
bevacizumab.
In conclusion, sarcomas are a heterogeneous group of
solid tumors in which hypoxia and HIF-1a activity play vary-
ing roles. A strong HIF-1a transcriptional program may be a
means of resistance for some sarcomas to anti-VEGF therapy.
In addition, HIF-1a inhibition to VEGF inhibition augments
destruction of the tumor vasculature in sarcomas, and this
strategy should be investigated in clinical trials.
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